www.marketwatch.com

www.marketwatch.com
Share

www.marketwatch.com

 •  October 13

After months of headlines about astronomical drug prices, a funny thing’s happening — drug costs are plummeting. One of the big surprises in the consumer price report for September released by the Labor Department was the big slowdown in medical-care costs. Also read: U.S. inflation surges again after hurricane boosts gas prices, CPI shows In the...

www.marketwatch.com

 •  October 11

Getty Images If successful, a new drug from the biotech Myovant Sciences Ltd. could treat two women’s health disorders, as well as prostate cancer. The drug, Relugolix, works to reduce estrogen in women and testosterone in men. The hormones are factors in two painful conditions affecting women, uterine fibroids and endometriosis, and in prostate...

www.marketwatch.com

 •  October 9

Sarepta Therapeutics Inc. SRPT, +1.08% shares surged nearly 3% in premarket trade Monday after RBC Capital Markets analyst Matthew Eckler said he sees a "compelling argument" for faster-than-normal approval of Sarepta's Duchenne muscular dystrophy drug golodirsen. Sarepta recently released positive early/mid-stage clinical trial results for the DMD...

www.marketwatch.com

 •  September 29

Merck announced early Friday that it plans to stop developing its two hepatitis C therapies. The decision follows a similar one by Johnson & Johnson earlier this month, with both Merck MRK, -0.40% and J&J JNJ, +0.42% saying that competitive considerations factored into their decisions. Now “the HCV category comes down to only 2 entrants,” AbbVie...

www.marketwatch.com

 •  September 25

Wallace Genocea Biosciences Inc. GNCA, +0.76% shares plummeted late Monday after the tiny Cambridge, Mass.-based biotech said it was shifting its drug development focus and cutting staff by 40%. Genocea shares dropped 49% to $2.72 after hours, following a brief halt. The company said it was halting spending and activities on its genital herpes...

www.marketwatch.com

 •  September 20

Alnylam Pharmaceuticals Inc. shares surged nearly 40% in extremely heavy morning trade Wednesday after the company said its patisiran therapy met its primary efficacy endpoint and all secondary endpoints in a key late-stage clinical trial. Patisiran, which is intended for the rare and progressive disease hereditary ATTR amyloidosis with...

www.marketwatch.com

 •  September 20

Getty Images When Pfizer Inc. began selling a cheaper version of Johnson & Johnson’s rheumatoid arthritis therapy Remicade, investors worried about the impact on sales of the blockbuster drug. But new competition turned out to be more of a nibble. Pfizer PFE, +1.52% now says there’s a reason for that, alleging that Johnson & Johnson JNJ, -1.48%...

www.marketwatch.com

 •  September 12

Sage Therapeutics Inc. shares plummeted 16% in extremely heavy morning trade Tuesday after the company said its brexanolone treatment missed primary and secondary endpoints in a late-stage clinical trial. By most accounts, the trial was a failure. But the true disappointment is that the drug won’t be able to help patients with the seizure disorder...

www.marketwatch.com

 •  September 8

Getty Images New Mexico sued several major pharmaceutical companies and wholesale drug distributors on Thursday, arguing the corporations are partly to blame for rampant opioid addiction rates in the state. The lawsuit, filed in state court in Santa Fe County, follows the lead of half a dozen other states that have also sued over the opioid crisis....

www.marketwatch.com

 •  September 6

Positive results for Sarepta Therapeutics Inc.’s new Duchenne muscular dystrophy drug in an early/mid-stage trial have sparked hopes for accelerated approval of the drug and propelled the company’s stock up as much as 14%. It’s also sure to spur comparisons to Sarepta’s SRPT, +13.75% last drug approval. Eteplirsen was the first U.S. drug approved...